Q&A

Diabetic Amyotrophy: A Rare but Striking Neuropathy

Author and Disclosure Information

 

PROGNOSIS AND MANAGEMENT

The course of diabetic amyo­trophy is variable. There is often gradual but incomplete restoration in muscle strength in correlation with aggressive glycemic control and physical therapy.2 The majority of patients have residual muscle weakness, absent patellar and/or ankle DTRs, exercise-related pain, stiffness, and difficulty walking or climbing stairs. Full recovery of strength only occurs in 10% to 20% of patients.6

Treatment with IV immunoglobulin or other immuno­suppressive drugs is controversial. According to a Cochrane review of immunotherapy for diabetic amyotrophy, only one completed controlled trial using IV methylprednisolone was found. There is currently no evidence to support use of immunoglobulins to halt progression and improve symptoms.8

Neuropathic pain may be ­difficult to control. The severe pain associated with diabetic amyotrophy begins to diminish several months after onset, but residual pain may persist for several years. Pregabalin, duloxetine, tricyclic antidepressants, antiepileptic drugs, and narcotic analgesics can be helpful.2,4 High doses of corticosteroids may lead to improvement of severe pain in some patients with diabetic amyotrophy.5

References >>

Pages

Recommended Reading

The Clinical Impact of Electronic Consultation in Diabetes Care
Type 2 Diabetes ICYMI
Mindfulness training shifts diabetic patients off autopilot
Type 2 Diabetes ICYMI
Personal health records help mentally ill patients with comorbidities access medical services
Type 2 Diabetes ICYMI
TNFR1 shown as marker for mortality risk in type 2 diabetes with kidney disease
Type 2 Diabetes ICYMI
Nanotherapies make inroads in wound regeneration
Type 2 Diabetes ICYMI
New cholesterol guidelines would add 13 million new statin users
Type 2 Diabetes ICYMI
Mindfulness Training Shifts Patients with Diabetes Off Autopilot
Type 2 Diabetes ICYMI
Rising to the Challenge of Glucose Control Before and After Surgery
Type 2 Diabetes ICYMI
Adding HbA1c doesn’t improve CVD risk assessment
Type 2 Diabetes ICYMI
Is Bariatric Surgery the Right Treatment Model for Obesity?
Type 2 Diabetes ICYMI